Greenfern Industries Limited (GFI) achieved impressive revenue growth of 789% during the six-month period ended 30 September 2022, due to the sale of GFI Pharma medicine products in Australia.
Despite this growth, GFI reported a net loss attributable to shareholders of $0.85 million for this period due to employee salaries, director fees and R&D expenses.
GFI has recently raised capital to fund its expansion and is continuing to seek growth opportunities.
The company is focusing on the medicinal cannabis, research and biotechnology sector, and is in the process of writing clinical trial protocols for low-dose Cannabidiol (CBD) registered medicines in Australia.
GFI also owns and runs a hydropower station, which generates renewable hydropower, and plans to update the generation facilities to increase power generation capacity.
See more
